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Abstract
Background: Although gastric caner (GC) remains the second cause of cancer-related death,
useful biomarkers for prognosis are still unavailable. We present here the attempt of mining novel
biomarkers for GC prognosis by using serum proteomics.
Methods: Sera from 43 GC patients and 41 controls with gastritis as Group 1 and 11 GC patients
as Group 2 was successively detected by Surface Enhanced Laser Desorption/ionization Time of
Flight Mass Spectrometry (SELDI-TOF-MS) with Q10 chip. Peaks were acquired by Ciphergen
ProteinChip Software 3.2.0 and analyzed by Zhejiang University-ProteinChip Data Analysis System
(ZJU-PDAS). CEA level were evaluated by chemiluminescence immunoassay.
Results: After median follow-up periods of 33 months, Group 1 with 4 GC patients lost was
divided into 20 good-prognosis GC patients (overall survival more than 24 months) and 19 poor-
prognosis GC patients (no more than 24 months). The established prognosis pattern consisted of
5 novel prognosis biomarkers with 84.2% sensitivity and 85.0% specificity, which were significantly
higher than those of carcinoembryonic antigen (CEA) and TNM stage. We also tested prognosis
pattern blindly in Group 2 with 66.7% sensitivity and 80.0% specificity. Moreover, we found that
4474-Da peak elevated significantly in GC and was associated with advanced stage (III+IV) and short
survival (p < 0.03).
Conclusion: We have identified a number of novel biomarkers for prognosis prediction of GC by
using SELDI-TOF-MS combined with sophisticated bioinformatics. Particularly, elevated expression
of 4474-Da peak showed very promising to be developed into a novel biomarker associated with
biologically aggressive features of GC.
Background
Gastric cancer (GC) is the second leading cause of cancer-
related death in the world and remains the top killing can-
cer in Asia including China [1,2]. Though GC mortality
has decreased markedly in most areas of the world, it is an
aggressive malignancy and is still difficult to be detected at
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early stage [3]. Early GC (EGC) tends to be detected in
countries with mass screening regimen using endoscopy
and radiography. However, the perceived inconvenience,
and discomforts caused by endoscopy and radiation have
resulted in low compliance. The majority of GC patients
are diagnosed at an advanced stage and died in 24 months
after operation because of recurrence and metastasis, with
only 27% 5-year overall survival rate in patients with
extended local resection [4]. Thus, it is of clinical impor-
tance to identify GC patients with poor prognosis for
intense treatment.
TNM staging system is used world-widely to direct thera-
peutic decision, predict prognosis, and stratify patients
into distinct groups with different risks for tumor-related
death [5]. However, due to intrinsic heterogeneity, cancer
patients with equivalent TNM stage, type and grade may
have quite different response to treatment and clinical
behavior. Moreover, changes of currently used serum-
derived biomarkers of GC such as carcinoembryonic anti-
gen (CEA), CA 19-9 and CA 72-4 usually appear in
advanced stage, and therefore have limited value in clinics
for predicting prognosis (lower than 40%) [6,7].
Although the combined use of these biomarkers have
shown certain improvement, their value is still far from
ideal [8-10].
Progresses in proteomics have presented new horizon and
led to novel techniques for mining serum biomarkers for
the detection of various carcinomas including GC [11].
SELDI-TOF-MS coupled with sophisticated bioinformat-
ics offers a sensitive, high-throughput, and rapid
approach for analyzing complex mixture of protein and
peptide [12,13]. Moreover, it is capable of inspecting the
whole proteome of serum and this meets our needs for
mining biomarkers based on disease condition. This
approach has been used to establish detection patterns for
various tumors [14], but its value in mining biomarkers
for prediction of prognosis and stage has seldom been
evaluated.
In the present prospective study, we classified GC patients
into good-prognosis group and poor-prognosis group
based on its survival characteristics. We discovered 5
novel biomarkers related to prognosis of GC by establish-
ing prognosis pattern with biomarker discovery set and
validated in an independent set. More importantly, we
found that peak at 4474 Da was significantly elevated in
poor-prognosis GC patients and patients with advanced
TNM stage.
Methods
Patient demographics
This study was approved by institutional review board
and conducted under the informed consent of patients.
Forty three consecutive GC patients and 41 gastritis
patients with dyspeptic symptoms as Group 1 in 2nd affil-
iated hospital of Zhejiang University School of Medicine,
China, from February 2003 and October 2004 were ini-
tially enrolled for biomarker mining in this study. All of
the 43 GC patients underwent surgical operations, includ-
ing 39 curative resections with D2 lymphadenectomy and
4 palliative operations due to the presence of metastasis.
All participants were histologically verified adenocarci-
noma or gastritis by gastroscopy. Median age of GC
patients was 58 years (range, 36~76 years) and that of
controls was 51 years (range, 38~73 years) (T-test p  =
0.09). Sex distribution was similar between GC patients
(29 males and 14 females) and controls (28 males and 13
females) (T-test p  = 0.93). Clinical stage was assessed
according to AJCC TNM stage (6th edition 2002).
Eleven GC patients with curative resection were subse-
quently enrolled as Group 2 for blind test. Post-operative
follow-up visits were performed every 3 months for the
first 2 years and then every 6 months up to 63 months or
death. With 1 GC patient from Group 1 died of surgical
complication, the follow-up rate was 94.3% (50/53) and
all 3 lost patients were also in Group 1. For the remaining
50 GC patients, median postoperative follow-up periods
were 33 months (3 to 63 months). Based on the fact that
median survival of GC is 24 months, we defined GC
patients with overall survival (OS) no more than 24
months as poor-prognosis group, and others as good-
prognosis [15,16]. As presented in Fig. 1, the media sur-
vival time (months) for all included GC patients (n = 54),
Survival curve for all included GC patients, good-prognosis  and poor-prognosis GC patients Figure 1
Survival curve for all included GC patients, good-
prognosis and poor-prognosis GC patients. The media 
survival time (months) for all included GC patients (n = 54), 
poor- prognosis (n = 25) and good-prognosis GC patients (n 
= 25) was 23, 12 and not reached, respectively. There was 
significantly statistical difference between poor-prognosis and 
good-prognosis groups (Log-rank test p = 0.00).Journal of Experimental & Clinical Cancer Research 2009, 28:126 http://www.jeccr.com/content/28/1/126
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poor- prognosis (n = 25) and good-prognosis GC patients
(n = 25) was 23, 12 and not reached, respectively. We thus
defined 20 patients as good-prognosis and left 19 as poor-
prognosis GC patients in Group 1, and 5 patients as good-
prognosis and left 6 as poor-prognosis in Group 2. None
of the gastritis patients developed GC during the period
and after follow-up for 48 months.
Blood processing and peak detection
All blood specimens were collected in the fasted state in
the morning before initiation of any treatment. Every
sample was rest at room temperature for 1-2 hours, centri-
fuged at 3 × g for 10 minutes. Serum samples were then
aliquoted into eppendorf tubes and frozen at -80°C until
use. Group 1 and 2 were detected in a separated date
according the following methods.
Serum samples were thawed on ice and centrifugated at 10
× g for 4 minutes with supernatants retained before detec-
tion. Ten μL of U9 denaturing buffer (9 M Urea, 2%
CHAPS, 1% DTT) was added to 5 μL of each serum sample
in a 96-well cell culture plate and agitated on a platform
shaker for 30 minutes at 4°C. The U9/serum mixture was
then loaded to 185 μL binding buffer (50 mM Tris-HCl,
pH9) and agitated again for 2 minutes at 4°C. Meanwhile,
Q10 chips were placed in the Bioprocessor (Ciphergen
Biosystems) and pre-activated with binding buffer (200
μL) for 5 minutes twice. The diluted samples (100 μL)
were then pipetted onto the spots on ProteinChip array.
After incubation for 60 minutes at 4°C, the chips were
washed three times with binding buffer (3 × 200 μL) and
twice with deionized water (2 × 200 μL). Finally, the chips
were removed from the bioprocessor and air-dried. Before
SELDI-TOF-MS analysis, saturated energy-absorbing mol-
ecule solution (sinapinic acid in 50% ACN and 0.5% TFA,
2 × 0.5 μL) was applied to each spot twice and air-dried.
The chips were detected on the PBS-II plus mass spectrom-
eter reader (Ciphergen Biosystems) and peak detection
was performed using the Ciphergen ProteinChip Software
3.2.0. Calibration of mass accuracy was determined using
the all-in-one peptide molecular mass standard. Data
were collected by averaging 140 laser shots with intensity
of 170 and detector sensitivity of 8. The highest mass of
60,000 m/z and optimized range of 2,000-20,000 Da were
set for analysis.
Serum CEA measurement
CEA level of all serum samples were evaluated in parallel
with SELDI-TOFMS analysis by chemiluminescence
immunoassay (CEA Regent Kit, Abbott Diagnostics).
Assays were carried out according to the manufacturer's
instructions by using ARCHITECT i2000 SR. The cutoff
value of CEA for prognosis prediction, detection and stage
discrimination of GC was set at 5 ng/mL.
Bioinformatics and statistic analysis
Bioinformatics and biostatistics were operated by Zhe-
jiang University-Proteinchip Data Analysis System (ZJU-
PDAS, http://www.zlzx.net), which was designed by Yu
and based on MATLAB Web Server 1.2.4 (The MathWorks
Inc.). ZJU-PDAS and detailed protocols have been
described in our previous report [17]. Spectra were
denoised by undecimated discrete wavelet transform,
based on the version 2.4 of the Rice Wavelet Toolbox, fol-
lowed by subtraction of baseline and calibration of mass.
The detected peaks were filtered by S/N more than 3 and
combined peaks in relative mass by 0.3%. Peaks appeared
in more than 10% of spectra were defined as peaks cluster.
Then we constructed a non-linear supportive vector
machine (SVM) classifier with a radial based function ker-
nel to discriminate the different groups. Leave-one-out
cross-validation approach was applied to estimate the
accuracy of the classifier. This approach leaves one sample
out to be test set and the remaining samples as the train-
ing set. The process continues until each sample has been
held in reserve one time as a test sample. Power of each
peak in discriminating different groups was evaluated by
the p value of Wilcoxon Rank Sum test. The top 10 peaks
with the least p value were selected and randomly input
into SVM in combination. The SVM model which
achieved the highest Youden's Index was determined as
the final pattern and the peaks were selected as candidate
biomarkers. Receiver operating curve (ROC) and survival
curve was performed with SPSS package version 11.0.
Results
Assay reproducibility
The reproducibility of the proteomic approach was deter-
mined by repeating one sera mixture 11 times using
standard procedures described above. The average coeffi-
cient of variance (CV) for the selected peaks with normal-
ized intensity was 17.2% and the CV for selected peak
mass was 0.03%.
Biomarkers for prognosis prediction and blind test
Total 50 peaks were qualified for establishing prognosis
pattern by comparing proteomic spectrum of 20 good-
prognosis GC patients with 19 poor-prognosis GC
patients in Group 1. The established prognosis pattern
consisted of 5 prognosis biomarkers with peaks at 4474,
4542, 6443, 4988, 6685 Da (see Additional file 1). This
prognosis pattern distinguished poor-prognosis group
from good-prognosis with sensitivity of 84.2% (16/19)
and specificity of 85.0% (17/20), while the sensitivity and
specificity of CEA only reached 52.6 (10/19) and 70.0
(14/20) correspondingly (Table 1). Moreover, the area
under ROC curve for the pattern was 0.861 (95% CI,
0.735 to 0.986), significantly higher than 0.436 (95% CI,
0.246 to 0.625) for CEA (Fig 2A). Peak at 4474 Da was
found to be the most informative biomarker with the areaJournal of Experimental & Clinical Cancer Research 2009, 28:126 http://www.jeccr.com/content/28/1/126
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under ROC curve of 0.695 (95% CI, 0.527 to 0.862), and
with significantly higher expression level in poor-progno-
sis group (Wilcoxon Rank Sum p = 0.04, Fig 3). Consider-
ing that TNM staging system has been commonly used to
predict prognosis, we also evaluated the predictive ability
of TNM stage by defining patients with stage I+II (n = 18)
as good prognosis and stage III+IV (n = 21) as poor prog-
nosis. However, our data indicate that the sensitivity and
specificity of TNM stage for predicting GC patients with
poor prognosis were 66.7% (14/21) and 72.2% (13/18)
respectively, both of which were inferior compared to the
prognosis pattern established in our study.
Group 2 with 5 good-prognosis and 6 poor-prognosis GC
patients were analyzed to blind test the prognosis predic-
tion pattern. The pattern acquired 66.7% (4/6) sensitivity
and 80.0% (4/5) specificity, and peak at 4474 Da had sig-
nificantly higher expression level in poor-prognosis GC
patients than good-prognosis patients (Intensity 965.42 ±
809.28 versus 425.31 ± 263.19, Fig 4).
Roles of prognosis biomarkers in GC pathogenesis
To investigate the role of prognosis biomarkers in carcino-
genesis of GC, we compared the proteomic spectrum of
43 GC patients with 41 non-cancer controls in Group 1
and total of 34 qualified peaks were determined. Six peaks
at 3957, 4474, 4158, 8938, 3941 and 4988 Da, respec-
tively, were identified as potential biomarkers for carcino-
genesis of GC and therefore composed the detection
pattern (see Additional file 1). Sensitivity and specificity
for our established detection pattern were 95.4% (41/43)
and 90.2% (37/41) respectively, while the parallel analy-
sis of serum CEA only achieved 34.9% (15/43) and 95.1%
(39/41), respectively (Table 1). The areas under ROC
curve was 0.934 (95% CI, 0.872 to 0.997) for the detec-
tion pattern and 0.628 (95% CI, 0.503 to 0.754) for CEA
(Fig 2B). Though peak at 3957 Da was the most useful
biomarker for screening, it highly expressed in non-cancer
controls. Among biomarkers up-regulated in GC, peak at
4474 Da was the most powerful discriminative biomarker
with ROC 0.716 (95% CI, 0.605 to 0.826; Wilcoxon Rank
Sum p < 0.001) (Fig. 5).
Table 1: Descriptive Statistics of Prognosis, Detection and Stage 
patterns for GC compared with CEA correspondingly.
Biomarkers ROC Sensitivity (%) Specificity (%) 
Prognosis pattern 0.861 84.2 (16/19) 85.0 (17/20)
CEA 0.436 52.6 (10/19) 70.0 (14/20)
Detection pattern 0.934 95.4 (41/43) 90.2 (37/41)
CEA 0.628 34.9 (15/43) 95.1 (39/41)
Stage pattern 0.800 79.2 (19/24) 78.9 (15/19)
CEA 0.753 50.0 (12/24) 84.2 (16/19)
The areas under Receiver Operating Characteristic (ROC)  curves for prognosis pattern and CEA (A), detection pattern  and CEA (B), stage pattern and CEA (C) Figure 2
The areas under Receiver Operating Characteristic 
(ROC) curves for prognosis pattern and CEA (A), 
detection pattern and CEA (B), stage pattern and 
CEA (C).Journal of Experimental & Clinical Cancer Research 2009, 28:126 http://www.jeccr.com/content/28/1/126
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To explore if the prognosis biomarkers also play a role in
GC progression, 19 patients with stage I+II and 24 with
stage III+IV from Group 1 were analyzed for stage discrim-
ination. Overall, 36 peaks were qualified and finally 6
peaks at 4474, 4060, 3957, 9446, 4988 and 5075 Da,
respectively, constructed the stage discriminating pattern
(see Additional file 1). This pattern could discriminate
stage III+IV with 79.2% (19/24) sensitivity and 78.9%
(15/19) specificity, while CEA only achieved 50.0% (12/
24) and 84.2% (16/19), respectively (Table 1). The area
under ROC curve was 0.800 (95% CI, 0.661 to 0.939) for
the established pattern and 0.753 (95% CI 0.60~0.90) for
CEA (Fig 2C). Interestingly, peak at 4474 Da was also the
most powerful biomarker for GC stage discrimination
with ROC of 0.732 (95% CI, 0.576 to 0.889, Wilcoxon
Rank Sum p = 0.01) and with significantly higher expres-
sion level in stage III+IV (Fig 6).
Discussion
GC is a heterogeneous disease and survival benefits could
be gained through early detection and intensive post-
operative treatment for selected patients. Evidence from
large randomized controlled trails supported TNM stage is
the most important index for postoperative treatment. Yet
inferior survival benefit made the majority of patients
over treated and we urgently need robust prognostic
biomarker to alter this fatal outcome. Unfortunately,
despite efforts with pharmacogemomics or gene-expres-
sion data, biomarkers with high and reliable predictive
value for GC prognosis are still unavailable. Intrinsic
genetic heterogeneity of GC have supported that panels of
multiple biomarkers may improve the predictive effi-
ciency. Serum proteomics conducted by SELDI-Protein-
Chip platform with bioinformatics to associate complex
patterns with disease has been attractive, as it is easily
accessible, non-invasive and clinically applicable. Novel
biomarkers detected by such approach have been reported
in various tumors, including prostate cancer [18,19], ovar-
ian cancer [20,21], brain cancer [22], colorectal cancer
Representative expression of the peak at 4474 Da (red) in  prognosis pattern Figure 3
Representative expression of the peak at 4474 Da 
(red) in prognosis pattern. Peak at 4474 Da was signifi-
cantly higher in poor-prognosis GC (upper panel), compared 
with good-prognosis GC (lower panel) in biomarker mining 
set. Wilcoxon Rank Sum p = 0.04.
Representative expression of the peak at 4474 Da (red) in  blind test set for prognosis pattern Figure 4
Representative expression of the peak at 4474 Da 
(red) in blind test set for prognosis pattern. Peak at 
4474 Da was high expressed in poor-prognosis GC (upper 
panel), compared with good-prognosis GC (lower panel) in 
blind test with 5 good-prognosis and 6 poor-prognosis GC 
patients.
Representative expression of the peak at 4474 Da (red) in  detection pattern Figure 5
Representative expression of the peak at 4474 Da 
(red) in detection pattern. Peak at 4474 Da was signifi-
cantly higher in GC (lower panel), compared with non-can-
cer controls (upper panel). Wilcoxon Rank Sum p < 0.001.Journal of Experimental & Clinical Cancer Research 2009, 28:126 http://www.jeccr.com/content/28/1/126
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[23,24], breast cancer [25,26], lung cancer [27] and GC
[28]. This approach has yielded informative biomarker
profiles in cancer detection with higher sensitivity and
specificity, but none of these studies have investigated the
correlation between serum protein profiles with progno-
sis of GC [29].
Though many efforts have been devoted to improve early
detection of GC, the majority of patients were diagnosed
at advanced stage. Identification of patients with potential
poor-prognosis would help us to optimize the clinical
treatment for GC patients. Histological grade, anatomi-
cally based TNM staging system, serum biomarkers, genes
and other factors have been used to predict prognosis so
far [5,15,30,31]. Currently, TNM staging system remains
the most widely used prognostic model, while newly
emerging biomarkers such as CEA, CA72-4 or its combi-
nation may provide additional prognostic information.
For example, Kochi et al demonstrated that patients with
elevated serum CEA levels were at significantly higher risk
of having GC recurrence than those with normal levels
[8]. However, as shown in several studies including the
present study, these serum biomarkers have limited pre-
dictive value due to their low sensitivities [6-9]. Therefore,
seeking new biomarkers with higher and more reliable
predictive value for malignancies has been of great interest
in both research and clinical settings.
After median follow-up period of 33 months, we divided
50 patients with follow-up result into biomarker mining
set (Group 1) and independent blind test set (Group 2).
Our data indicated that the prognosis pattern consisted of
5 potential prognosis biomarkers (peaks at 4474, 4542,
6643, 4988 and 6685 Da) could distinguish the two dif-
ferent groups with 85.0% sensitivity and 84.2% specifi-
city, both of which are significantly higher than
traditional TNM stage and/or serum CEA. More impor-
tantly, we discovered that 4474-Da peak, a novel peak has
not been reported previously, was the most informative
peak for prognosis prediction. To further confirm these
findings, a blind test with 11 independent GC patients
was performed. Our data showed that the sensitivity and
specificity of the prognosis pattern were 66.7% and
80.0%, respectively. Moreover, a significantly higher
expression level of peak at 4474 Da in poor-prognosis GC
group was also observed in independent blind test set.
Additionally, we investigated the role of prognosis
biomarkers in the carcinogenesis and progression of GC.
With comparison of GC and gastritis group, we confirmed
that prognosis biomarkers with peak at 4474, 4988 Da
were highly expressed in GC group and indicated that they
may play a role in carcinogenesis of GC. Furthermore,
peak at 4474 Da may contribute to the occurrence of GC
owing to its most significantly elevated expression in GC.
With comparison of different stage of GC, we discovered
that 4474-Da peak especially up-regulated in GC with
advanced stage. In a word, peak at 4474 Da was not only
a candidate biomarker for prognosis prediction, but also
a biomarker play an important role in the carcinogenesis
and development of GC.
Conclusion
In this study, by using SELDI-TOF-MS combined with
sophisticated bioinformatics, we have identified a
number of novel biomarkers for prognosis prediction of
GC. Moreover, peak at 4474 Da was found to be signifi-
cantly associated with aggressive characteristics of GC.
Thus, identification of peaks at 4474Da may facilitate
prognosis prediction and decision making for clinically
intensive treatment and worthy of further investigation on
a larger scale. In the coming era of personalized medicine,
protein profiling attempts like this study may provide
important basis for individualized therapy to cancer
patients.
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Representative expression of the peak at 4474 Da (red) in  stage pattern Figure 6
Representative expression of the peak at 4474 Da 
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